文献速递支持与姑息治疗

免疫检查点抑制剂与静脉血栓栓塞事件

Immune checkpoint inhibitors for cancer and venous thromboembolic events.
PubMed 文献 · Eur J Cancer · 2021-10-15

该回顾性研究纳入2854例接受免疫检查点抑制剂(ICI)治疗的患者,采用自身对照风险区间设计,比较治疗前后两年VTE发生风险。结果显示ICI启动后6个月VTE风险7.4%、1年13.8%,VTE发生率较治疗前升高约4倍(HR 4.98)。

要点

  • ICI启动后VTE风险6个月7.4%、1年13.8%
  • ICI启动后VTE风险较前升高约4倍(HR 4.98)
  • 深静脉血栓风险升高5.7倍,肺栓塞风险升高4.75倍

核心结论

  • 接受ICI治疗的患者VTE发生率较高,且启动ICI后VTE风险显著增加。

研究设计与样本

  • 单中心回顾性研究纳入2854例接受ICI治疗的患者,采用自身对照风险区间设计,比较治疗前两年与治疗后两年VTE风险。

主要发现

  • 2854例患者中男性1640例(57.5%),平均年龄64±13岁。
  • ICI启动后6个月VTE风险为7.4%,1年风险为13.8%。
  • ICI启动后VTE风险较治疗前升高约4倍(HR 4.98,95%CI 3.65-8.59,p<0.001)。
  • 深静脉血栓风险升高5.7倍(HR 5.70,95%CI 3.79-8.59,p<0.001),肺栓塞风险升高4.75倍(HR 4.75,95%CI 3.20-7.10,p<0.001)。
  • 黑色素瘤病史和年龄较大预测VTE风险较低,Khorana风险评分较高、高血压病史和VTE病史预测VTE风险较高。

临床怎么用

  • 肿瘤内科医生在启动ICI治疗时应评估患者VTE风险,尤其关注Khorana评分较高、有高血压或VTE病史者。
  • ICI治疗期间需警惕VTE事件,如深静脉血栓和肺栓塞的临床表现。

局限性

  • 研究为单中心回顾性设计,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. There are limited data on the risk for developing venous thromboembolism (VTE) among patients on an ICI. METHODS: This was a retrospective study of 2854 patients who received ICIs at a single academic centre. VTE events, defined as a composite of deep vein thrombosis or pulmonary embolism, were identified by individual chart review and blindly adjudicated using standard imaging criteria. A self-controlled risk-interval design was applied with an 'at-risk period' defined as the two-year period after and the 'control period', defined as the two-year before treatment. The hazard ratio (HR) was calculated using a fixed-effect proportional hazards model. RESULTS: Of the 2854 patients, 1640 (57.5%) were men; the mean age was 64 ± 13 years. The risk for VTE was 7.4% at 6 months and 13.8% at 1 year after starting an ICI. The rate of VTE was > 4-fold higher after starting an ICI (HR 4.98, 95% CI 3.65-8.59, p < 0.001). There was a 5.7-fold higher risk for deep vein thrombosis (HR 5.70, 95% CI 3.79-8.59, p < 0.001) and a 4.75-fold higher risk for pulmonary embolism (HR 4.75, 95% CI 3.20-7.10, p < 0.001). Comparing patients with and without a VTE event, a history of melanoma and older age predicted lower risk of VTE, while a higher Khorana risk score, history of hypertension and history of VTE predicted higher risk. CONCLUSIONS: The rate of VTE among patients on an ICI is high and increases after starting an ICI.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gong J, Drobni ZD, Alvi RM, et al. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer. 2021. PMID: 34662835. doi:10.1016/j.ejca.2021.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。